With reference to the above captioned subject and pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are pleased to inform that, Board ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Medi-Caps Limited's Board approved audited standalone and consolidated financial results for Q4 and FY 2025-26. Standalone revenue declined marginally to ₹230.59 Lacs from ₹241.66 Lacs, with the company reporting a net loss of ₹-13.87 Lacs versus a profit of ₹55.51 Lacs in FY 2024-25, attributed to volatile real estate market conditions. Consolidated revenue stood at ₹1244.85 Lacs but the group incurred a much larger net loss of ₹-303.75 Lacs due to unstable political conditions in its major US market. The Board also re-appointed Praveen Shrivastava & Company as internal auditor for FY 2026-27. Auditors Rawka & Associates gave an unmodified (clean) opinion on both standalone and consolidated results.
The sharp swing to losses on both standalone and consolidated basis, coupled with mentions of volatile real estate conditions and unstable political conditions in the US, signals deteriorating financial health and could weigh on investor sentiment near-term.